Overview
- A comprehensive review published Tuesday in The Lancet pooled lab studies, clinical trials and real‑world surveillance of billions of mRNA doses to assess safety and public‑health impact.
- The analysis reports high short‑term protection: about 87% effectiveness against infection, 93% against hospitalization, and 94% against death within 14–42 days after vaccination.
- Serious side effects are very rare; the review gives myocarditis estimates of roughly 12.6 cases per million for Pfizer and 35.6 cases per million for Moderna and notes SARS‑CoV‑2 infection carries a higher myocarditis risk.
- Authors highlight the mRNA platform’s wider promise for influenza, RSV and personalized cancer vaccines while noting ongoing trials and recent regulatory reviews of next‑generation mRNA products.
- The paper urges sustained post‑licence surveillance, clearer public communication to rebuild trust, and increased investment in manufacturing, storage and technology transfer to improve equity in low‑ and middle‑income countries.